⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for metastatic head and neck squamous cell carcinoma

Every month we try and update this database with for metastatic head and neck squamous cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckNCT05172258
Head and Neck S...
Metastatic Head...
Metastatic Hypo...
Metastatic Lary...
Metastatic Oral...
Metastatic Orop...
Recurrent Head ...
Recurrent Hypop...
Recurrent Laryn...
Recurrent Oral ...
Recurrent Oroph...
Stage IV Hypoph...
Stage IV Laryng...
Stage IV Lip an...
Stage IV Oropha...
Biopsy
Biospecimen Col...
Computed Tomogr...
Ipatasertib
Pembrolizumab
18 Years - National Cancer Institute (NCI)
Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal DiseaseNCT03868020
Metastatic Head...
Metastatic Squa...
Computed Tomogr...
Fluciclovine F1...
Positron Emissi...
18 Years - M.D. Anderson Cancer Center
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor MalignanciesNCT03590054
Stage III Cutan...
Stage IV Cutane...
Locally Advance...
Locally Advance...
Metastatic Head...
Metastatic Mali...
Metastatic Mela...
Metastatic Urot...
Non-Small Cell ...
Stage IB Lung C...
Stage III Cutan...
Stage III Lung ...
Stage III Urete...
Stage IIIA Lung...
Stage IIIB Lung...
Stage IIIC Lung...
Stage IV Cutane...
Stage IV Lung C...
Stage IV Ureter...
Stage IVA Lung ...
Stage IVB Lung ...
Abexinostat
Pembrolizumab
18 Years - University of California, San Francisco
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaNCT04643379
Recurrent Head ...
Metastatic Head...
Olaparib
Pembrolizumab
Carboplatin
Peripheral bloo...
18 Years - Washington University School of Medicine
Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell CarcinomaNCT06211335
Locally Recurre...
Metastatic Head...
Refractory Head...
Losartan
Pembrolizumab
Stereotactic Bo...
18 Years - University of California, Davis
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaNCT04643379
Recurrent Head ...
Metastatic Head...
Olaparib
Pembrolizumab
Carboplatin
Peripheral bloo...
18 Years - Washington University School of Medicine
Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCCNCT03813836
Metastatic Head...
Recurrent Head ...
Pembrolizumab
18 Years - University College, London
Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by SurgeryNCT01468896
Metastatic Head...
Recurrent Head ...
Unresectable He...
Cetuximab
Edodekin alfa
Laboratory Biom...
18 Years - National Cancer Institute (NCI)
Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT03498378
Head and Neck S...
Avelumab
Palbociclib
Cetuximab
18 Years - University of California, San Diego
Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell CancerNCT00494182
Metastatic Head...
Metastatic Squa...
Metastatic Squa...
Metastatic Squa...
Metastatic Squa...
Recurrent Head ...
Recurrent Hypop...
Recurrent Laryn...
Recurrent Oral ...
Recurrent Oroph...
Carboplatin
Paclitaxel
Sorafenib
18 Years - M.D. Anderson Cancer Center
INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT05359692
Metastatic Head...
Advanced Malign...
Recurrent Head ...
INCAGN01876
retifanlimab
18 Years - 99 YearsIncyte Corporation
Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and EpacadostatNCT03823131
Metastatic Head...
Recurrent Head ...
Unresectable He...
ImmunoPulse
Epacadostat
Pembrolizumab
CORVax
Tavokinogene te...
18 Years - University of California, San Francisco
Standard and Delayed FDG PET/CT After Chemoradiation Therapy in Assessing Patients With Metastatic Head and Neck Squamous Cell CancerNCT03575949
Metastatic Head...
Metastatic Mali...
Computed Tomogr...
Fludeoxyglucose...
Positron Emissi...
18 Years - M.D. Anderson Cancer Center
Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell CarcinomaNCT06211335
Locally Recurre...
Metastatic Head...
Refractory Head...
Losartan
Pembrolizumab
Stereotactic Bo...
18 Years - University of California, Davis
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) ProgramNCT06265285
Advanced Esopha...
Advanced Renal ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Esophageal Carc...
Gastroesophagea...
Hepatocellular ...
Locally Advance...
Lung Non-Small ...
Malignant Solid...
Metastatic Colo...
Metastatic Cuta...
Metastatic Esop...
Metastatic Head...
Metastatic Urot...
Recurrent Esoph...
Recurrent Head ...
Renal Cell Carc...
Stage III Renal...
Stage IV Colore...
Stage IV Cutane...
Stage IV Renal ...
Unresectable Cu...
Unresectable Es...
Urothelial Carc...
Home Health Enc...
Nivolumab
Patient Monitor...
Questionnaire A...
18 Years - Mayo Clinic
Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT03522584
Metastatic Head...
Recurrent Head ...
Durvalumab
Laboratory Biom...
Stereotactic Bo...
Tremelimumab
Hypofractionate...
18 Years - University of Washington
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid TumorsNCT04007744
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Gast...
Metastatic Gast...
Metastatic Head...
Metastatic Lung...
Metastatic Mali...
Metastatic Mela...
Metastatic Urot...
Recurrent Head ...
Refractory Lung...
Stage IV Cutane...
Stage IV Lung C...
Unresectable Ma...
Unresectable Me...
Pembrolizumab
Sonidegib
18 Years - Mayo Clinic
Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCCNCT03813836
Metastatic Head...
Recurrent Head ...
Pembrolizumab
18 Years - University College, London
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckNCT04862650
Clinical Stage ...
Metastatic Head...
Metastatic Hypo...
Metastatic Lary...
Metastatic Oral...
Metastatic Orop...
Pathologic Stag...
Recurrent Head ...
Recurrent Hypop...
Recurrent Laryn...
Recurrent Oral ...
Recurrent Oroph...
Squamous Cell C...
Stage IV Hypoph...
Stage IV Laryng...
Stage IV Lip an...
Stage IVA Hypop...
Stage IVA Laryn...
Stage IVA Lip a...
Stage IVB Hypop...
Stage IVB Laryn...
Stage IVB Lip a...
Stage IVC Hypop...
Stage IVC Laryn...
Stage IVC Lip a...
Carboplatin
Cemiplimab
Paclitaxel
18 Years - Ohio State University Comprehensive Cancer Center
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckNCT05172258
Head and Neck S...
Metastatic Head...
Metastatic Hypo...
Metastatic Lary...
Metastatic Oral...
Metastatic Orop...
Recurrent Head ...
Recurrent Hypop...
Recurrent Laryn...
Recurrent Oral ...
Recurrent Oroph...
Stage IV Hypoph...
Stage IV Laryng...
Stage IV Lip an...
Stage IV Oropha...
Biopsy
Biospecimen Col...
Computed Tomogr...
Ipatasertib
Pembrolizumab
18 Years - National Cancer Institute (NCI)
(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell CarcinomaNCT05747625
Head and Neck S...
Metastatic Head...
Stage IV Cutane...
Panitumumab
Zirconium Zr 89...
Positron Emissi...
Computed Tomogr...
Electronic Heal...
19 Years - Vanderbilt-Ingram Cancer Center
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckNCT04862650
Clinical Stage ...
Metastatic Head...
Metastatic Hypo...
Metastatic Lary...
Metastatic Oral...
Metastatic Orop...
Pathologic Stag...
Recurrent Head ...
Recurrent Hypop...
Recurrent Laryn...
Recurrent Oral ...
Recurrent Oroph...
Squamous Cell C...
Stage IV Hypoph...
Stage IV Laryng...
Stage IV Lip an...
Stage IVA Hypop...
Stage IVA Laryn...
Stage IVA Lip a...
Stage IVB Hypop...
Stage IVB Laryn...
Stage IVB Lip a...
Stage IVC Hypop...
Stage IVC Laryn...
Stage IVC Lip a...
Carboplatin
Cemiplimab
Paclitaxel
18 Years - Ohio State University Comprehensive Cancer Center
Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by SurgeryNCT01468896
Metastatic Head...
Recurrent Head ...
Unresectable He...
Cetuximab
Edodekin alfa
Laboratory Biom...
18 Years - National Cancer Institute (NCI)
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck CancersNCT05063552
Clinical Stage ...
Metastatic Head...
Metastatic Hypo...
Metastatic Lary...
Metastatic Lip ...
Metastatic Nasa...
Metastatic Naso...
Metastatic Phar...
Metastatic Sino...
Recurrent Head ...
Recurrent Hypop...
Recurrent Laryn...
Recurrent Lip a...
Recurrent Nasop...
Recurrent Phary...
Recurrent Sinon...
Stage IV Hypoph...
Stage IV Laryng...
Stage IV Lip an...
Stage IV Nasoph...
Stage IV Oropha...
Stage IV Sinona...
Atezolizumab
Bevacizumab
Biospecimen Col...
Carboplatin
Cetuximab
Cisplatin
Computed Tomogr...
Docetaxel
Echocardiograph...
Magnetic Resona...
Positron Emissi...
18 Years - National Cancer Institute (NCI)
INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT05359692
Metastatic Head...
Advanced Malign...
Recurrent Head ...
INCAGN01876
retifanlimab
18 Years - 99 YearsIncyte Corporation
Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCCNCT05156970
Recurrent Head ...
Metastatic Head...
Camrelizumab
Cisplatin
Docetaxel
Apatinib Mesyla...
Carboplatin
18 Years - 75 YearsShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid TumorsNCT04007744
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Gast...
Metastatic Gast...
Metastatic Head...
Metastatic Lung...
Metastatic Mali...
Metastatic Mela...
Metastatic Urot...
Recurrent Head ...
Refractory Lung...
Stage IV Cutane...
Stage IV Lung C...
Unresectable Ma...
Unresectable Me...
Pembrolizumab
Sonidegib
18 Years - Mayo Clinic
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) ProgramNCT06265285
Advanced Esopha...
Advanced Renal ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Esophageal Carc...
Gastroesophagea...
Hepatocellular ...
Locally Advance...
Lung Non-Small ...
Malignant Solid...
Metastatic Colo...
Metastatic Cuta...
Metastatic Esop...
Metastatic Head...
Metastatic Urot...
Recurrent Esoph...
Recurrent Head ...
Renal Cell Carc...
Stage III Renal...
Stage IV Colore...
Stage IV Cutane...
Stage IV Renal ...
Unresectable Cu...
Unresectable Es...
Urothelial Carc...
Home Health Enc...
Nivolumab
Patient Monitor...
Questionnaire A...
18 Years - Mayo Clinic
Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCCNCT05156970
Recurrent Head ...
Metastatic Head...
Camrelizumab
Cisplatin
Docetaxel
Apatinib Mesyla...
Carboplatin
18 Years - 75 YearsShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaNCT04196283
Advanced Solid ...
ABBV-368
Tilsotolimod
Nab-paclitaxel
ABBV-181
18 Years - AbbVie
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: